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Background: Epstein-Barr virus is a human herpesvirus that infects a majority of the human population. Primary
infection of Epstein-Barr virus (EBV) causes the syndrome infectious mononucleosis. This virus is also associated with
several cancers, including Burkitt’s lymphoma, post-transplant lymphoproliferative disorder and nasopharyngeal
carcinoma. As all herpesvirus family members, EBV initially replicates lytically to produce abundant virus particles,
then enters a latent state to remain within the host indefinitely.
Methods: Through a genetic screen in Drosophila, we determined that reduction of Drosophila Tor activity altered
EBV immediate-early protein function. To further investigate this finding, we inhibited mTOR in EBV-positive cells
and investigated subsequent changes to lytic replication via Western blotting, flow cytometry, and quantitative PCR.
The student T-test was used to evaluate significance.
Results: mTOR, the human homolog of Drosophila Tor, is an important protein at the center of a major signaling
pathway that controls many aspects of cell biology. As the EBV immediate-early genes are responsible for EBV lytic
replication, we examined the effect of inhibition of mTORC1 on EBV lytic replication in human EBV-positive cell lines.
We determined that treatment of cells with rapamycin, which is an inhibitor of mTORC1 activity, led to a reduction
in the ability of B cell lines to undergo lytic replication. In contrast, EBV-positive epithelial cell lines underwent
higher levels of lytic replication when treated with rapamycin.
Conclusions: Overall, the responses of EBV-positive cell lines vary when treated with mTOR inhibitors, and this may
be important when considering such inhibitors as anti-cancer therapeutic agents.
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Epstein-Barr virus (EBV) is a human herpesvirus which
has infected a large majority of the world’s human popula-
tion. This virus infects epithelial cells of the nasopharynx,
where it replicates in a lytic or productive manner, as well
as B lymphocytes, where the virus enters a latent state [1].
EBV is associated with a plethora of diseases, including in-
fectious mononucleosis, lymphomas (Burkitt’s lymphoma,
Hodgkins lymphoma, post-transplant lymphoproliferative
disorder), epithelial-based cancers (including nasopha-
ryngeal carcinoma), multiple sclerosis, and the rare but
deadly X-linked lymphoproliferative syndrome [2]. The
prevalence of this virus, along with its potential for ser-
ious disease, necessitate the study of means to inhibit* Correspondence: aladamso@uncg.edu
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unless otherwise stated.lytic replication, as well as treatments to kill EBV-
positive cancer cells.
EBV lytic replication commences upon infection of new
cells, or upon reactivation of the latent virus within cells.
During lytic replication the first wave of EBV protein ac-
tivity includes the immediate-early BZLF1 (Z) and BRLF1
(R) proteins. The Z and R proteins are both absolutely
necessary for lytic replication to proceed. These are
transcription factors that activate transcription from the
promoters of the next wave of EBV genes, the early
genes. The early genes encode proteins that act to repli-
cate the viral genome. Lastly, the late genes are expressed
to provide the virion structural elements [1].
The Z and R proteins act not only as transcriptional
activators, but also physically interact with several cellular
proteins including CREB-binding protein (CBP), in order
to promote viral replication in lieu of cellular activitiesral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pathways, including the p38, JNK, and ERK pathways
[5-7]. Activation of these pathways has been found to be
essential for EBV lytic replication. In addition, both Z
and R are SUMO-1 modified, which negatively affects Z
transcriptional activity, while enhancing R transcriptional
activity [8-11]. A potential means of inhibiting viral repli-
cation in cells would be to suppress the activity of Z and/
or R. Hindering key viral protein/cellular protein interac-
tions may lead to such suppression of Z and R activities,
and therefore inhibit EBV lytic replication.
mTOR is a kinase at the heart of a major signaling path-
way. mTOR can be found in two different protein com-
plexes, mTORC1 and mTORC2 [12,13]. Extracellular
signals such as various nutrient levels and growth factors
impinge on the mTORC1 pathway to control a variety of
processes including protein translation, autophagy, cell
growth, and mitochondrial metabolism [12-14]. Pathways
that activate mTORC1 include the MAPK ERK and Akt
signaling pathways, both of which can be activated by
phosphatidylinositol 3 kinase (PI3 kinase) [15]. As part
of the mTORC1 complex, mTOR promotes the phos-
phorylation of downstream targets including p70S6K
and 4EBP1. These events promote ribosome biogenesis
and cap-dependent translation, respectively [13,15,16].
Rapamycin is a specific inhibitor of mTOR activity
within mTORC1. Rapamycin, also an immunosuppres-
sant, complexes with the protein FKBP-12; this complex
then binds to mTOR and inhibits its kinase activity [16].
As inhibition of mTOR subsequently inhibits protein
translation and cell growth, rapamycin is an excellent can-
didate for anti-tumor treatment. In fact rapamycin (or
similar mTOR inhibitors) has gained interest for the treat-
ment of cancers, including EBV-associated post-transplant
lymphoproliferative disease [17-19].
Previous studies have shown that inhibition of mTOR
by treatment with rapamycin is effective in inhibiting
Kaposi’s sarcoma herpesvirus (KSHV) lytic replication
[20]. The inhibition of lytic replication appears to be
due to the inhibition of translation of the immediate-early
protein, RTA [20]. Another mTOR inhibitor, Torin1, was
found to inhibit viral replication for the herpesvirus
members cytomegalovirus, herpes simplex virus 1, and
murine gammaherpesvirus 68 [21]. These three viruses
were much less sensitive to rapamycin treatment [21].
In the case of human cytomegalovirus, the inhibition of
mTOR did not greatly affect the immediate-early pro-
teins, as for KSHV, but appeared to inhibit downstream
replication events [21].
In a Drosophila model system, we identified Tor as a
modifier of Z and R activities. Translating this finding to
the context of lytically-replicating EBV, we found that
mTORC1 inhibition via rapamycin treatment yielded dif-
ferent effects in B cell versus epithelial cell lines. Whilerapamycin treatment of EBV-positive B cells inhibited
lytic replication, rapamycin treatment increased lytic
replication in the EBV-positive epithelial cell lines tested,
suggesting that the effects of mTOR inhibition differ
greatly, in respect to lytic replication, between different
cell types. These effects upon EBV lytic replication ap-
pear to be, at least in part, due to differential influences
upon Z and R gene expression.
Results
Loss of Tor modified GMR-Z and GMR-R phenotypes in
Drosophila
We have previously expressed the Z and R genes in
Drosophila eye tissue, which yielded significant mutant
eye phenotypes (Figure 1C, D, G, H) [22,23]. Such pheno-
types allowed us to perform genetic screens to identify host
cellular modifiers of Z or R activity. One such screen in-
volved crossing our Z and R expressing flies to Drosophila
tumor suppressor mutants [23]. An interesting finding was
that when R-expressing flies (GMR-R3) were crossed to Tor
(the fly homolog of mTOR) mutant fly lines (TorDeltaP
and Tork17004, which both decrease Tor levels [24,25];
the TorDeltaP/+and Tork17004/+flies alone have wild-type-
appearing eyes) the progeny had more wild-type eyes,
suggesting that reduced Tor levels suppressed R activity in
eye tissue (Figure 1E, F). Conversely, when Z-expressing
flies (GMR-Z) were crossed to the same Tor mutant fly
lines, their progeny had a much more severe mutant
phenotype, suggesting that the reduction of Tor actu-
ally increased Z activity (Figure 1I, J). Comparing the
Tor-modified GMR-R3 and GMR-Z phenotypes (Figure 1F
and J), it appears that the decrease of Tor activity im-
pacted the GMR-Z phenotype more so than the GMR-R3
phenotype. The GMR-Z/Tor phenotype is much more se-
vere than GMR-Z/+; the GMR-R3/Tor phenotype is mod-
erately improved in relation to the GMR-R3/+phenotype.
This suggests that the loss of Tor may impact Z activity
more so than R activity.
Inhibition of mTOR via rapamycin decreases EBV lytic
replication in B cell lines, but not in epithelial cell lines
As loss of Tor affected Z and R activity in Drosophila
eye cells, we hypothesized that a reduction of mTOR ac-
tivity in human cells would affect Z and/or R activity
and thus alter EBV lytic replication within EBV-positive
cells. To this end, we treated the latently-infected, EBV-
positive epithelial cell line AGS-BDneo with 0, 1, 5, or
10 nM rapamycin for 24 hr prior to the induction lytic
replication. We performed Western blot analyses to
examine levels of the early protein BMRF1, an indicator
of early lytic replication events, as well as the levels of Z,
R, and tubulin (Figure 2A). Quantification of the BMRF1
protein levels relative to tubulin levels indicated that the
loss of mTORC1 activity enhanced lytic replication in
Figure 1 Loss of Tor alters Z and R activity in a Drosophila model system. A-B. Wild-type eye. C-D. GMR-R3 heterozygote. Note the rough
eye phenotype and extra small bristles in D. E-F. GMR-R3/Tor transheterozygote. Note the more wild-type structure and reduction of extra small
bristles. G-H. GMR-Z heterozygote. I-J. GMR-Z/Tor transheterozygote. Note the flattening of the ommatidia in J.
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EBV-positive epithelial cells lines (AGS-BX1 and D98/
HR1) yielded similar results (Figure 2C). The rapamycin
dose that had the most significant effect upon lytic rep-
lication in these cells, without impairing cell growth (5
nM) was very effective at inhibiting mTOR activity, as
evidenced by the ability of this dose to inhibit the phos-
phorylation of the mTOR target p70S6K in these cells
(Figure 2E, lane 2).
As the doses used were relatively low doses of rapamycin,
we tested to see if a higher dose of rapamycin would have a
different effect upon lytic replication in EBV-positive
epithelial cell lines, in an effort to inhibit lytic replica-
tion. We treated AGS-BDneo cells with 100 nM rapa-
mycin for 24 hr prior to induction of lytic replication
and performed Western blot analysis to examine the
levels of BMRF1. We found that the higher dose of 100
nM rapamycin was still unable to inhibit lytic replica-
tion, relative to untreated (Figure 3A, lane 5).
EBV biology is cell-type specific, as the virus lytically
replicates in epithelial cells to produce abundant pro-
geny viral particles, but enters a latent state in B cells,
immortalizing those cells to remain a part of those cells
indefinitely [1]. To examine the effects of mTOR inhib-
ition on EBV lytic replication in EBV-positive B cells, we
treated the latently infected B cell line Raji with a dosage
series of rapamycin for 24 hr then disrupted latency in
these cells. Western blot analysis was performed for
BMRF1, and the resulting BMRF1 levels quantified and
standardized relative to tubulin levels (Figure 2A, B).
In contrast to the epithelial cells, rapamycin treatment
inhibited lytic replication in B cells, in a dose-dependent
manner. Additional EBV-positive B cell lines were exam-
ined, including P3HR1, Daudi, and EBfaV-GFP (derived
from B958), and all showed results similar to Raji, i.e. that
rapamycin treatment was effective in inhibiting early lytic
replication (Figure 2C). The rapamycin dose most effective
in decreasing lytic replication in B cells, without impairingcell growth (5 nM), was also very effective in inhibiting
the phosphorylation of p70S6K by mTOR in Raji cells
(Figure 2E, lane 2).
As for AGS-BDneo, we examined whether a higher dose
of rapamycin would be more effective than 5 nM rapa-
mycin at inhibiting early lytic replication in Raji cells.
Figure 3B shows that 5 nM was very effective at inhibiting
BMRF1 expression (Figure 3B, lane 4), and a higher dose
(100 nM) was not more effective (Figure 3B, lane 5).
As BMRF1 expression represents early gene expression,
we next examined how mTOR inhibition via rapamycin
altered late gene expression. Therefore we treated the
EBV-positive cell representatives AGS-BDneo and Raji
with 5 nM rapamycin for 24 hr, induced the cells into
lytic replication, and performed flow cytometry to assess
early (BMRF1) and late (VCA) gene expression (the
VCA antibody used did not recognize VCA on West-
ern blots, thus flow cytometry was used) (Figure 4). For
AGS-BDneo cells we found that, similar to the results of
Figure 2, treatment with 5 nM rapamycin caused BMRF1,
and VCA levels, to significantly increase in rapamycin-
treated induced cells, relative to untreated induced cells
(Figure 4A). For Raji cells we were not able to detect VCA
(due to the lack of VCA gene expression in these cells)
(Figure 4B), thus we treated the latently infected B cell line
EBfaV-GFP with rapamycin and induced these cells into
lytic replication, and found that rapamycin caused BMRF1,
and VCA levels to significantly decrease in rapamycin-
treated induced cells, in comparison to untreated in-
duced cells (Figure 4C). To examine the end result of
lytic replication, the formation of infectious viral parti-
cles, after treatment with rapamycin, we treated EBfaV-
GFP cells with 0 or 5 nM rapamycin, induced the cells
into lytic replication, and two days later removed the
media, filtered out the cells with a 0.2 μm filter, and
placed the filtered media on Raji cells for two days. The
EBV virus within EBfaV-GFP harbors the GFP gene thus
cells infected with this virus are GFP-positive [26]. We
Figure 2 Inhibition of mTORC1 alters early lytic replication in EBV-positive cells. A. AGS-BDneo or Raji cells were treated with 0, 1, 5, or 10
nM rapamycin 24 hr prior to induction of lytic replication. Western blot analysis was performed with anti-BMRF1, anti-Z, anti-R, and anti-tubulin
antibodies. Representative blots are shown. B. The BMRF1 levels from Western blots (in triplicate) were quantified and standardized to tubulin
levels. The resulting BMRF1 protein levels are presented, relative to induced cells (with no rapamycin treatment). C. BMRF1 levels of a panel of
EBV-positive cells treated with 5 nM rapamycin, induced, and analyzed as in parts A and B above. Dark bars are epithelial cell lines, light bars are
B cell lines. D. Z and R levels from the Western blots in part A were quantified and standardized to tubulin levels. The resulting Z and R protein
levels are presented, relative to induced cells (with no rapamycin treatment). E. Inhibition of mTOR with 5 nM rapamycin inhibits mTOR activity.
Raji and AGS-BDneo cells were treated with 0 or 5 nM rapamycin for 2 days, then subjected to Western blot analysis with anti-phospho-p70S6K
and total p70S6K antibodies.
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positive Raji cells, and found that the rapamycin treat-
ment significantly lowered the number of viral particles
being produced by EBfaV-GFP cells, as judged by the
number of Raji cells infected (Figure 4D).
Treatment of EBV-positive cell lines with rapamycin does
not impact cell viability
To ensure that rapamycin treatment did not impact the via-
bility of the cells used in this study, we treated Raji, EBfaV-
GFP, and AGS-BDneo cells with 0 or 5 nM rapamycin for
24 hr, and induced the cells into lytic replication. Viableversus dead cells were determined by flow cytometry
(Figure 5A). The results indicate that rapamycin treatment
did not negatively impact cell viability, thus eliminating
the possibility that a loss of viability of the cells could ac-
count for the alteration of lytic replication seen above. We
did find, however, that 5 nM rapamycin decreased the cell
proliferation of AGS-BDneo, Raji, and EBfaV-GFP cells
(Figure 5B), as would be expected [17-19].
Short-term effects of mTOR inhibition on EBV lytic replication
Previous studies have demonstrated that treatment of cells
with low levels of rapamycin inhibits mTORC1 activity for
Figure 3 Higher doses of rapamycin are not effective in inhibiting EBV lytic replication in AGS-BDneo cells. A, AGS-BDneo cells, B, Raji
cells. Cells were treated with rapamycin as indicated for 24 hr prior to the induction of lytic replication. Western blot analysis was performed with
anti-BMRF1 and anti-tubulin antibodies. The BMRF1 levels were quantified and standardized to tubulin levels. The resulting BMRF1 protein levels
are presented, relative to induced cells (with no rapamycin treatment).
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tiated and the inhibitory effect of rapamycin is supposedly
lost [27,28]. To investigate whether our dose (5 nM) of
rapamycin had a different short-term effect on our cell
lines, we incubated Raji cells (as a B cell representative)
and D98/HR1 cells (as an epithelial cell representative)
with 5 nM rapamycin for 24, 18, 6, 4, 2, 1, or 0 hr. At time
0, the cells were washed to remove the rapamycin treat-
ment. Also at time 0 the cells were induced into lytic
replication. Western blot analysis was performed to
examine BMRF1, Z, R, and tubulin levels; BMRF1, Z,
and R levels were quantified and standardized to tubulin
levels (Figure 6). B cells that had the rapamycin washed
off at time 0 (Figure 6A) had a time-dependent decrease
in lytic replication, with the inhibitory effect elicited
after 4 hr of treatment, continuing to decrease in a
time-dependent manner until 18–24 of rapamycin treat-
ment. Similar trends were noted with Daudi and P3HR1
cells (data not shown). Conversely, epithelial cells exhibited
a time-dependent increase in lytic replication, with the
strongest effect at 24 hr of rapamycin treatment (Figure 6B).
Therefore, shorter exposure times did not show a different
course of action of rapamycin in regard to lytic replication
in either of these cell types.
For all cell lines tested, treatment with rapamycin 18–
24 hr prior to induction yielded the most significant results.
Rapamycin treatment at the time of induction (0 hr) yielded
a milder change, and treatment 24 hr post-induction
yielded little to no change in BMRF1 levels (data not
shown).
Z and R transcript and protein levels are altered by
rapamycin treatment in a cell-type dependent manner
Our initial work in Drosophila suggested that loss of Tor
activity in Drosophila eye cells led to altered Z and Ractivity (greater Z activity and reduced R activity), with
the most significant impact on Z activity (judging by the
severity of the phenotypes in Figure 1). Thus we next
sought to examine whether inhibition of mTOR in EBV-
positive cells could alter expression levels of Z or R. To
this end we treated the EBV-positive cell lines Raji and
AGS-BDneo with 5 nM rapamycin, induced cells into lytic
replication, and subsequently harvested RNA from the
cells. Quantitative RT-PCR was performed (Figure 7A).
We found that while rapamycin treatment had no/little ef-
fect upon the level of GAPDH (control) transcripts, rapa-
mycin treatment did affect transcript levels of both Z and
R, in a cell-type dependent manner (Figure 7A). In the
Raji B cell line, induction alone caused an average 166-
fold increase in Z transcripts over uninduced cells; this
was decreased to 13 fold when cells were pre-treated with
5 nM rapamycin. Similarly, induction caused a nearly 20
fold increase in R transcripts in Raji cells; this was de-
creased to approximately 2 fold after rapamycin treat-
ment. Conversely, in the AGS-BDneo epithelial cell line,
rapamycin treatment increased both Z and R transcript
levels, from an average of 5 fold to about 8 fold for Z, and
an average of 2 to 3 fold for R, in relation to uninduced
cells. It is worth noting that while it appears that Z and R
transcripts are much more abundant in Raji cells than epi-
thelial cells (Figure 7A), there actually was a higher base-
line of Z and R transcript levels present in AGS-BDneo
cells, including the uninduced cells, than in Raji cells. By
qRT-PCR we found that while the GAPDH control tran-
script levels varied between AGS-BDneo and Raji by a
ΔCT of 0.6 (representing a 1.5 fold increase of GAPDH
transcript in the AGS-BDneo cells), the Z transcript levels
differed by a ΔCT of 7.8 between uninduced AGS-BDneo
and Raji cells (representing an over 200-fold increase of
baseline Z transcripts in the AGS-BDneo cells). The same
Figure 4 Inhibition of mTOR alters late lytic replication in EBV-
positive cells. AGS-BDneo (A), Raji (B), and EBfaV-GFP (C) cells were
left untreated or treated with 5 nM rapamycin for 24 hr prior to
induction of lytic replication, as indicated. 48 hr post-infection
cells were immunostained for BMRF1 or VCA, and the staining was
analyzed by flow cytometry. The percent positive cells is presented. D.
EBfaV-GFP cells were left untreated or treated with 5 nM rapamycin
for 24 hr prior to induction of lytic replication, as indicated. 2 days
post-induction the media from each condition was filtered and
placed on Raji cells for 2 days. The number of resulting infected Raji
cells was quantified, as judged by GFP, and the percent of infection
presented. * = P < 0.05 relative to uninduced, untreated control cells;
# = P < 0.05 relative to induced, untreated cells.
Figure 5 Rapamycin treatment does not alter EBV-positive cell
viability, but does decrease cell proliferation. Raji, EBfaV-GFP, and
AGS-BDneo cells were left untreated or treated with 5 nM rapamycin
for 24 hr prior to induction of lytic replication, as indicated. 24 hr
later the viability of cells and cell density were determined by flow
cytometry. The percentage of viable cells is presented in A, the cell
density (total cells/ml) is presented in B.
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versus Raji cells.
The Z and R transcript levels correlated with subse-
quent protein levels, such that rapamycin treatment sig-
nificantly reduced Z and R protein levels in Raji cells(and EBfaV-GFP cells) (Figure 7B). Rapamycin treatment
of AGS-BDneo cells increased Z and R protein levels; Z
demonstrated a significant increase, while R levels were
typically increased only moderately (Figure 7B). For
rapamycin-treated AGS-BDneo cells the levels of Z were
significantly higher than those of R, suggesting that the
increase in lytic replication in these cells may be due
more to rapamycin-mediated effects upon Z rather than
R. Rapamycin-based changes in Z and R expression levels
were also demonstrated in Figure 2A (shown quantified in
2D) as well as in Figure 6A and B.
Discussion
We discovered that modulation of mTOR activity alters
EBV lytic replication, beginning with a genetic screen in
Drosophila that demonstrated that loss of Tor enhanced
Z activity, and suppressed R activity, in Drosophila tissues
(Figure 1). It logically followed that inhibition of mTOR in
human cells would alter the lytic replication of EBV, as lytic
replication is dependent upon both Z and R activities.
We found that the rapamycin-mediated inhibition of
mTOR had varying effects upon lytic replication amongst
different EBV-positive cell lines. Inhibition of mTOR
inhibited lytic replication in B cell lines, while in contrast
Figure 6 Shorter exposure times to rapamycin are not more effective at altering BMRF1 production in either B or epithelial cells. Raji
(A) and D98/HR1 (B) cells were treated with 5 nM rapamycin for the times indicated prior to induction. The rapamycin-containing media was
washed off the cells at time 0 (the time of induction). Two days post-induction proteins were harvested and Western blot analyses were
performed with anti-BMRF1, anti-Z, anti-R, and anti-tubulin antibodies. The resulting bands were quantified and standardized to tubulin levels.
Resulting BMRF1 protein levels (middle panels), and Z and R levels (lower panels) are presented, relative to 0 hr.
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and 4). The effects upon lytic replication were not time-
dependent, as would be found if the action of rapamycin
was negated by a negative feedback loop, as short-term
doses of rapamycin yielded the same results as longer-
term doses [i.e. in B cells rapamycin inhibited lytic replica-
tion at all time points, and in epithelial cells rapamycin
enhanced lytic replication at all time points (Figure 6)].
Furthermore, in an attempt to have epithelial cells mimic
the B cell response to rapamycin, we treated epithelial
cells with higher doses of rapamycin, yet lytic replication
in these cells was still enhanced by the higher doses
(Figure 3).
As the immediate-early proteins Z and R are responsible
for initiating lytic replication, and lytic replication was
altered upon rapamycin treatment, it follows that the in-
hibition of mTOR likely altered these proteins’ levels or
functions. In the case of KSHV, Nichols et al. found that
treatment of KSHV-positive cells with 12 nM rapamycin
inhibited the KSHV immediate-early protein RTA from
being translated [20]. This logically led to a loss of lytic
replication in these cells [20]. However for other her-
pesviruses such as human cytomegalovirus, treatment
with 20 nM rapamycin or 250 nM Torin1 had little ef-
fect upon immediate-early protein levels, yet caused adecrease in the number of viral particles produced via lytic
replication [21]. Therefore, it does not appear that inhib-
ition of mTORC1 simply leads to an inhibition of viral
protein translation for all viruses. In our study we found
that rapamycin treatment actually altered the transcript
levels of Z and R, such that in B cells Z and R transcript
levels were decreased when lytic replication was induced
in the presence of rapamycin, while in epithelial cells Z
and R transcript levels were increased when lytic replica-
tion was induced in the presence of rapamycin (Figure 7A).
The resulting Z and R protein levels correlated with the
transcript levels (Figure 7B), and with the amount of Z
protein binding to Z-response elements (ZREs; data not
shown); this correlates with the levels of lytic replication
that ensued in each cell type.
Thus it appears that mTORC1 activity plays a role in
lytic replication at least in part by regulating the expres-
sion of the Z and R genes. mTORC1 activity has been
shown to have a significant role in regulating the activity
of a variety of transcription factors (reviewed in [29]), in-
cluding at least one transcription factor (YY1) that is
known to regulate Z and R promoter activation [30,31].
That inhibition of mTORC1 yields opposing effects in
the transcription of Z and R in B versus epithelial cell
lines may have to do with different transcription factor
Figure 7 Z and R transcript and protein levels are altered by rapamycin treatment. Raji and AGS-BDneo cells were treated with 5 nM
rapamycin for 24 hr prior to induction of lytic replication. A. Total RNA was isolated and qRT-PCR was performed with GAPDH (control)-, Z-, or
R-specific primers, in triplicate. The mean fold expression over uninduced cells, standardized to GAPDH levels, is presented. B. Z and R protein
levels from Western blots (in triplicate) were quantified and standardized to tubulin levels. The resulting Z and R protein levels from AGS-BDneo,
Raji, and EBfaV-GFP cells are presented, relative to induced cells (with no rapamycin treatment). * = P < 0.05 relative to induced cells (with no
rapamycin treatment); # = P < 0.05 relative to R levels within same cell type.
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scription factors are affected by loss of mTOR activity.
A working model based on our study is presented in
Figure 8. Overall, we have found that B cells require ac-
tive mTORC1 for efficient lytic replication. In contrast,
epithelial cells do not require active mTORC1 to engage
in productive lytic replication.
Conclusions
mTOR function is central to many different cellular pro-
cesses, and viruses have evolved to manipulate the mTOR
pathways to aid their replication [32,33]. Our investi-
gations have provided evidence that EBV replication is
dependent upon the mTOR pathway, at least in B cells, and
that inhibiting this pathway in B cells greatly limits EBV
lytic replication. However direct inhibition of mTOR inFigure 8 Model of rapamycin action upon EBV lytic replication.epithelial cells has the opposite effect, and enhances EBV
lytic replication. These results are important to take into
account when considering the use of mTOR inhibitors as
anti-viral or anti-cancer therapeutic agents.
Materials and methods
SEMs
Flies were sputter coated with gold in a Pelco model 3
sputter coater 91000. Images were taken on a Hitachi S-
4800 SEM microscope.
Cell lines
D98/HR1, a latently infected, EBV-positive epithelial cell
line created by the fusion of HeLa cells with EBV-positive
P3HR1 cells were maintained in Ham’s F12 medium supple-
mented with 10% fetal bovine serum along with penicillin,
streptomycin, and fungicide. AGS-BDneo and AGS-
BX1 are EBV-positive gastric carcinoma cell lines (gifts
of L. Hutt-Fletcher) and were maintained in Ham’s F12
supplemented with 10% fetal bovine serum along with
penicillin, streptomycin, fungicide, and 500 μg/ml G418.
Raji, Daudi, and P3HR1 (ATCC) are latently infected,
EBV-positive B cell lines derived from Burkitt’s lymphoma.
EBfaV-GFP is a derivative of the B958 cell line, in which
the viral LMP2 gene was replaced by the EGFP gene
driven by the CMV immediate-early promoter [26]. All
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with 10% fetal bovine serum along with penicillin,
streptomycin, and fungicide.Cell treatments
Cells were treated with rapamycin (in DMSO, Sigma-
Aldrich) for the times indicated. Cells not treated with
either compound were treated with the vehicle, DMSO
(Sigma-Aldrich). If cells were washed prior to induction,
cells had their media removed, were washed one time
with 1xPBS, then regular media added back. If un-
washed, then the rapamycin or DMSO remained present
in the media until cells were harvested.Disruption of viral latency
B cells were treated with 20 ng/ml TPA and 3 mM sodium
butyrate, and epithelial cells were treated with 5 ng/ml
TPA and 0.75 mM sodium butyrate (higher doses of these
inducing chemicals caused significant cell death of our
AGS cell lines) for 24–48 hr as indicated (both from
Sigma-Aldrich).Protein preparation
Cells were collected, washed twice with 1xPBS, resus-
pended in ELB lysis buffer (0.25 M NaCl, 0.1% NP40,
50 mM HEPES pH 7, 5 mM EDTA and protease inhibi-
tors), and sonicated. The lysed cells were centrifuged
and the supernatants quantified for protein concentra-
tion prior to SDS-PAGE.Western blotting
Equal amounts of protein (20–40 μg) were loaded onto
10% SDS-PAGE gels and electrophoresed. Proteins were
transferred to Immobilon (Millipore) membranes.Immunoblotting
Blots were blocked with blocking buffer (5% nonfat dried
milk, with 0.1% Tween-20, 1xPBS) for 2 hr to overnight.
Primary antibodies: anti-BMRF1 (Capricorn), anti-tubulin
(Developmental Hybridoma Bank), anti-R (Argene) and
anti-Z (Argene or Santa Cruz) were diluted 1:200 in block-
ing buffer; anti-phospho-p70S6K and anti-total p70S6K
(Cell Signaling) were diluted 1:1000 in blocking buffer; all
were incubated with the blots 1 hr to overnight, washed
with 0.1% Tween-20 in 1xPBS 3 times for 10 min each,
and incubated in secondary antibody (goat-anti-mouse
HRP or goat-anti-rabbit-HRP, Jackson Immunoresearch)
diluted 1:10,000 in blocking buffer, for 1 hr. Blots were
washed as before and visualized with Super Signal
(Pierce). Images and quantification were performed
with a BioRad gel documentation apparatus.Viability and cell density testing
Cells were treated with rapamycin for 24 hr then induced.
Cells were collected and diluted in Guava ViaCount so-
lution. After a five minute incubation, cell viability and
cell density (total cells/ml) were determined by flow
cytometry with a Guava InCyte flow cytometer.
Flow cytometry
Cells were treated as indicated, washed with PBS, and
fixed with 60% acetone in PBS for 10 min at 4°. Cells
were washed with PBS/0.5% BSA, incubated with anti-
BMRF1 (Capricorn) or anti-VCA (Argene) antibodies
[1:200 in Incubation mix (0.3% BSA, 5% goat serum,
0.1% Triton X in PBS)] for 1 hr at room temperature,
washed with PBS/0.5% BSA, and incubated in donkey-
anti-mouse-FITC (1:400 in Incubation mix) (Jackson
Immunoresearch) for 1 hr at room temperature. Cells
were washed with PBS/0.5% BSA, resuspended in PBS,
and analyzed with a Guava EasyCyte flow cytometer
(Millipore).
qRT-PCR
Total RNA from treated cells was isolated with the
RNeasy mini kit (QIAGEN). qRT-PCR reactions (20 μL)
were performed with the Power SYBR Green RNA-to-CT™
1-Step kit (Applied Biosystems), 10 ng of total RNA, and 20
pmol of each primer, as per the manufacturer’s directions.
Primers used for Z were: 5’-ACTGCTGCAGCACTACC
GTGAGGTG-3’ (forward) and 5’-GAAATTTAAGAGA
TCCTCGTCTAA-3’ (reverse) (creating a 150 bp product).
Primers for R were: 5’-ATGAGGCCTAAAAAGGATGG
CTT-3’ (forward) and 5’-TGAGGACGTTGCAGTAGT
CAG-3’ (reverse) (creating a 100 bp product). Reactions
were performed and analyzed with an Applied Biosystems
Step One Plus real time PCR machine.
Quantification and statistics
Western blots were quantified with ChemiDoc XRS soft-
ware (BioRad) and flow cytometry data was quantified
with Guava EasyCyte analysis software (Millipore). Expe-
riments were done in triplicate, and the student T-test
(two-tailed) used to evaluate significance. A P value <0.05
was considered significant.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
BTL carried out the quantitative RT-PCR. BDS carried out immunoassays.
ALA conceived of the study, participated in its design and coordination,
performed the SEMs, immunoassays, and flow cytometry, and wrote the
manuscript. All authors read and approved the final manuscript.
Acknowledgments
This work was supported by NIH grants 1R15AI072699-01 and
1R15AI098015-01A1 to A.L.A.
Adamson et al. Virology Journal 2014, 11:110 Page 10 of 10
http://www.virologyj.com/content/11/1/110I would like to thank Dr. Lindsey Hutt-Fletcher for the AGS cell lines, and I
would like to thank the following undergraduate students for their assistance
with this work: Jason Hansen and Jennifer Awuku.
Received: 2 April 2014 Accepted: 5 June 2014
Published: 11 June 2014References
1. Kieff E, Rickinson AB: Epstein-Barr virus and its replication. In Field's
Virology. Volume 2. 5th edition. Edited by Knipe DM, Howley PM.
Philadelphia: Lippincott Williams & Wilkins; 2007:2603–2654.
2. Rickinson AB, Kieff E: Epstein-Barr virus. In Field's Virology. Volume 2. 5th
edition. Edited by Knipe DM, Howley PM. Philadelphia: Lippincott Williams &
Wilkins; 2007:2655–2700.
3. Adamson AL, Kenney S: The Epstein-Barr virus BZLF1 protein interacts
physically and functionally with the histone acetylase CREB-binding protein.
J Virol 1999, 73:6551–6558.
4. Swenson JJ, Holley-Guthrie E, Kenney SC: Epstein-Barr virus immediate-
early protein BRLF1 interacts with CBP, promoting enhanced BRLF1
transactivation. J Virol 2001, 75:6228–6234.
5. Chang Y, Lee HH, Chen YT, Lu J, Wu SY, Chen CW, Takada K, Tsai CH:
Induction of the early growth response 1 gene by Epstein-Barr virus lytic
transactivator Zta. J Virol 2006, 80:7748–7755.
6. Lee YH, Chiu YF, Wang WH, Chang LK, Liu ST: Activation of the ERK signal
transduction pathway by Epstein-Barr virus immediate-early protein Rta.
J Gen Virol 2008, 89:2437–2446.
7. Adamson AL, Darr D, Holley-Guthrie E, Johnson RA, Mauser A, Swenson J,
Kenney S: Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1
activate the ATF2 transcription factor by increasing the levels of
phosphorylated p38 and c-Jun N-terminal kinases. J Virol 2000, 74:1224–1233.
8. Adamson AL: Effects of SUMO-1 upon Epstein-Barr virus BZLF1 function
and BMRF1 expression. Biochem Biophys Res Commun 2005, 336:22–28.
9. Adamson AL, Kenney S: Epstein-barr virus immediate-early protein BZLF1
is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J Virol
2001, 75:2388–2399.
10. Chang LK, Lee YH, Cheng TS, Hong YR, Lu PJ, Wang JJ, Wang WH, Kuo CW,
Li SS, Liu ST: Post-translational modification of Rta of Epstein-Barr virus
by SUMO-1. J Biol Chem 2004, 279:38803–38812.
11. Liu ST, Wang WH, Hong YR, Chuang JY, Lu PJ, Chang LK: Sumoylation of
Rta of Epstein-Barr virus is preferentially enhanced by PIASxbeta. Virus
Res 2006, 119:163–170.
12. Corradetti MN, Guan KL: Upstream of the mammalian target of rapamycin:
do all roads pass through mTOR? Oncogene 2006, 25:6347–6360.
13. Laplante M, Sabatini DM: mTOR Signaling. Cold Spring Harb Perspect Biol
2012, 4:a011593.
14. Schieke SM, Finkel T: Mitochondrial signaling, TOR, and life span. Biol
Chem 2006, 387:1357–1361.
15. Laplante M, Sabatini DM: mTOR signaling at a glance. J Cell Sci 2009,
122:3589–3594.
16. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N: mTOR, translation
initiation and cancer. Oncogene 2006, 25:6416–6422.
17. Cen O, Longnecker R: Rapamycin reverses splenomegaly and inhibits
tumor development in a transgenic model of Epstein-Barr Virus-related
Burkitt's lymphoma. Mol Cancer Ther 2011, 10(4):679–686.
18. Garber K: Rapamycin may prevent post-transplant lymphoma. J Natl
Cancer Inst 2001, 93:1519.
19. Vaysberg M, Balatoni CE, Nepomuceno RR, Krams SM, Martinez OM:
Rapamycin inhibits proliferation of Epstein-Barr virus-positive B-cell
lymphomas through modulation of cell-cycle protein expression.
Transplantation 2007, 83:1114–1121.
20. Nichols LA, Adang LA, Kedes DH: Rapamycin blocks production of KSHV/
HHV8: insights into the anti-tumor activity of an immunosuppressant
drug. PLoS One 2011, 6:e14535.
21. Moorman NJ, Shenk T: Rapamycin-resistant mTORC1 kinase activity is
required for herpesvirus replication. J Virol 2010, 84:5260–5269.
22. Adamson AL, Wright N, LaJeunesse DR: Modeling early Epstein-Barr virus
infection in Drosophila melanogaster: the BZLF1 protein. Genetics 2005,
171:1125–1135.
23. Adamson AL, LaJeunesse DR: A Study of Epstein-Barr Virus BRLF1 Activity
in a Drosophila Model System. Sci World J 2012, 2012:1–9.24. Zhang H, Stallock JP, Ng JC, Reinhard C, Neufeld TP: Regulation of cellular
growth by the Drosophila target of rapamycin dTOR. Genes Dev 2000,
14:2712–2724.
25. Oldham S, Montagne J, Radimerski T, Thomas G, Hafen E: Genetic and
biochemical characterization of dTOR, the Drosophila homolog of the
target of rapamycin. Genes Dev 2000, 14:2689–2694.
26. Speck P, Longnecker R: Epstein-Barr virus (EBV) infection visualized by
EGFP expression demonstrates dependence on known mediators of EBV
entry. Arch Virol 1999, 144:1123–1137.
27. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T,
Sabatini DM, Gray NS: An ATP-competitive mammalian target of rapamycin
inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem
2009, 284:8023–8032.
28. Thoreen CC, Sabatini DM: Rapamycin inhibits mTORC1, but not
completely. Autophagy 2009, 5:725–726.
29. Laplante M, Sabatini DM: Regulation of mTORC1 and its impact on gene
expression at a glance. J Cell Sci 2013, 126:1713–1719.
30. Montalvo EA, Cottam M, Hill S, Wang YJ: YY1 binds to and regulates
cis-acting negative elements in the Epstein-Barr virus BZLF1 promoter.
J Virol 1995, 69:4158–4165.
31. Zalani S, Coppage A, Holley-Guthrie E, Kenney S: The cellular YY1 transcription
factor binds a cis-acting, negatively regulating element in the Epstein-Barr
virus BRLF1 promoter. J Virol 1997, 71:3268–3274.
32. Spangle JM, Munger K: The human papillomavirus type 16 E6
oncoprotein activates mTORC1 signaling and increases protein synthesis.
J Virol 2010, 84:9398–9407.
33. O'Shea C, Klupsch K, Choi S, Bagus B, Soria C, Shen J, McCormick F, Stokoe
D: Adenoviral proteins mimic nutrient/growth signals to activate the
mTOR pathway for viral replication. EMBO J 2005, 24:1211–1221.
doi:10.1186/1743-422X-11-110
Cite this article as: Adamson et al.: Inhibition of mTORC1 inhibits lytic
replication of Epstein-Barr virus in a cell-type specific manner. Virology
Journal 2014 11:110.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
